Talphera Inc narrows third-quarter loss but faces FDA challenge due to patient enrollment delays
TLPH Talphera Inc
$1.03 -1.43%
View chart & analysis → - 1Talphera Inc recorded a third-quarter loss of $0.05 per share.
- 2Patient enrollment over the last 2-3 months decreased by 85-90% compared to the same period in 2025.
- 3Management attributed the increase in operating expenses to nafamostat (Niyad) development and pre-launch commercial preparations.
So what's the key point?
Talphera Inc reduced its losses in the third quarter, but patient enrollment has dropped significantly. Costs have increased due to drug development and preparations for its market launch.
Source Earnings Whispers +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.